MIR520H: MIR520H is an upregulated miRNA that has been associated with poor prognosis in various diseases, including liver cancer (HCC) [PMC7827149]. In a study analyzing the TCGA miRNA-seq dataset of liver cancer, MIR520H was found to be one of the upregulated miRNAs [PMC7378193]. Another study found that MIR520H was upregulated in women with recurrent pregnancy loss (RPL) compared to normal controls [PMC5572592]. Additionally, MIR520H has been implicated in breast cancer cell resistance to paclitaxel by attenuating the stability of the tumor suppressor PTEN and activating the Akt pathway [PMC8394096]. Furthermore, MIR520H is part of a cluster of miRNAs on chromosome 19 known as C19MC, which has been associated with stem cell biology and tumorigenesis [PMC8508841]. In breast invasive carcinoma, cumulative expression analysis revealed upregulation of MIR520H along with other C19MC miRNAs [PMC6193703]. Overall, upregulation of MIR520H has been consistently associated with poor prognosis in various diseases. Its involvement in tumorigenesis and resistance to treatment highlights its potential as a therapeutic target. However, further research is needed to fully understand its mechanisms and potential clinical applications.